Literature DB >> 22035341

Methadone: a review of drug-drug and pathophysiological interactions.

Bhushan M Kapur1, Janine R Hutson, Tamanna Chibber, Adriana Luk, Peter Selby.   

Abstract

Numerous established and potential drug interactions with methadone are clinically important in people treated with methadone either for addiction or for chronic pain. Methadone users often have comorbidities and are prescribed drugs that may interact with methadone. Methadone is extensively metabolized by cytochrome P450 (CYP) 3A4 and to a lesser extent by CYP 1A2, 2D6, 2D8, 2C9/2C8, 2C19, and 2B6. Eighty-six percent of methadone is protein bound, predominately to α1-acid glycoprotein (AGP). Polymorphisms in or interactions with CYPs that metabolize methadone, changes in protein binding, and other pathophysiological conditions affect the pharmacokinetic properties of methadone. It is critical for health care providers who treat patients on methadone to have adequate information on the interactions of methadone with other drugs of abuse and other medications. We set out to describe drug-drug interactions as well as physiological and pathophysiological factors that may impact the pharmacokinetics of methadone. Using MEDLINE, we conducted a systematic search for papers and related abstracts published between 1966 and June 2010. Keywords that included methadone, drug-drug interactions, CYP P450 and AGP identified a total of 7709 papers. Other databases, including the Cochrane Database of Systematic Reviews and Scopus, were also searched; an additional 929 papers were found. Final selection of 286 publications was based on the relevance of each paper to the topic. Over 50 such interactions were found. Interactions of methadone with other drugs can lead to increased or decreased methadone drug levels in patients and result in potential overdose or withdrawal, respectively. The former can contribute to methadone's fatality. Prescribers of methadone and pharmacists should enquire about any new medications (including natural products and over-the-counter medications) periodically, and especially when an otherwise stable patient suddenly experiences drug craving, withdrawal or intoxication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035341     DOI: 10.3109/10408363.2011.620601

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  17 in total

1.  Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Authors:  Taha Ahmad; Samie Sabet; Donald A Primerano; Lauren L Richards-Waugh; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

2.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

3.  Use of methadone for opioid weaning in children: prescribing practices and trends.

Authors:  Kazim Giby; Régis Vaillancourt; Nisha Varughese; Christina Vadeboncoeur; Annie Pouliot
Journal:  Can J Hosp Pharm       Date:  2014-03

4.  Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain.

Authors:  Tara A Macey; Melissa B Weimer; Elizabeth M Grimaldi; Steven K Dobscha; Benjamin J Morasco
Journal:  J Opioid Manag       Date:  2013 Sep-Oct

5.  Prevalence and correlates of intentional substance use to reduce illicit opioid use in a Canadian setting.

Authors:  Jan Klimas; Wing Yin Mok; Stephanie Lake; M Eugenia Socías; Kora DeBeck; Kanna Hayashi; Evan Wood; M-J Milloy
Journal:  J Subst Use       Date:  2022

6.  Effects of Methadone on Corrected Q-T Interval Prolongation in Critically Ill Children.

Authors:  Travis S Heath; Rachel G Greenberg; Susan R Hupp; David A Turner; Christoph P Hornik; Kanecia O Zimmerman
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 7.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

8.  Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone.

Authors:  Chin-Chuan Hung; Mu-Han Chiou; Yu-Ning Teng; Yow-Wen Hsieh; Chieh-Liang Huang; Hsien-Yuan Lane
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

9.  Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma.

Authors:  Fouad Chiadmi; Joël Schlatter
Journal:  Anal Chem Insights       Date:  2015-08-26

10.  A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.

Authors:  Laura R Marks; Satish Munigala; David K Warren; David B Liss; Stephen Y Liang; Evan S Schwarz; Michael J Durkin
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.